TherapeuticsMD Announces $7 Million Private Placement
03 Ottobre 2022 - 12:50PM
Business Wire
Maturity Date of Financing Agreement Extended
to October 31, 2022, with the Ability to Extend to November 30,
2022, if Additional Capital is Raised
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the
“Company”) an innovative, leading women’s healthcare company,
announced today that it received a $7 million private investment in
the Company’s Series A Preferred Stock from Rubric Capital
Management LP (“Rubric”). TherapeuticsMD expects to use the
proceeds from the transaction for working capital.
Under the terms of the Company’s financing agreement with its
lender, Sixth Street Specialty Lending, Inc. (“Sixth Street”), upon
receipt of the investment and the delivery to Sixth Street of
warrants to acquire 125,000 shares of the Company’s common stock at
an exercise price of $0.01 per share, the maturity date of the
financing agreement was automatically extended until October 31,
2022. The Company has the option to further extend the maturity
date until November 30, 2022, if it receives additional equity
capital of $7 million.
The Company's Board of Directors and management team continue
its active strategic alternatives process to strengthen the
Company’s long-term financial position.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. TherapeuticsMD’s products are designed to
address the unique changes and challenges women experience through
the various stages of their lives with a therapeutic focus in
family planning, reproductive health, and menopause management.
TherapeuticsMD is committed to advancing the health of women and
championing awareness of their healthcare issues. To learn more
about TherapeuticsMD, please visit https://www.therapeuticsmd.com/
or follow us on Twitter: @TherapeuticsMD and on Facebook:
TherapeuticsMD.
Cautionary Notes Regarding Forward Looking Statements
This press release contains forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to the Company’s objectives, plans and
strategies as well as statements, other than historical facts, that
address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may
occur in the future. These statements are often characterized by
terminology such as “believes,” “hopes,” “may,” “anticipates,”
“should,” “intends,” “plans,” “will,” “expects,” “estimates,”
“projects,” “positioned,” “strategy” and similar expressions and
are based on assumptions and assessments made in light of
management’s experience and perception of historical trends,
current conditions, expected future developments and other factors
believed to be appropriate. Forward-looking statements in this
press release are made as of the date of this press release, and
the Company undertakes no duty to update or revise any such
statements, whether as a result of new information, future events
or otherwise. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties, many
of which are outside of the Company’s control. Important factors
that could cause actual results, developments and business
decisions to differ materially from forward-looking statements are
described in the sections titled “Risk Factors” in the Company’s
filings with the Securities and Exchange Commission, including its
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as Current Reports on Form 8-K, and include the
following: whether the company will be able to refinance the
indebtedness under its term loan facility, and, if not, whether the
Company will be able to continue as a going concern; whether the
Company will be able to raise capital to fund its operations; the
effects of management transitions; the effects of the COVID-19
pandemic; the Company’s ability to maintain or increase sales of
its products; the Company’s ability to develop and commercialize
IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing
necessary therefor; the effects of supply chain issues on the
supply of the Company’s products; the potential of adverse side
effects or other safety risks that could adversely affect the
commercialization of the company’s current or future approved
products or preclude the approval of the Company’s future drug
candidates; the Company’s ability to protect its intellectual
property; the length, cost and uncertain results of future clinical
trials; the Company’s reliance on third parties to conduct its
manufacturing, research and development and clinical trials; the
ability of the Company’s licensees to commercialize and distribute
the Company’s products; the ability of the Company’s marketing
contractors to market ANNOVERA; the availability of reimbursement
from government authorities and health insurance companies for the
Company’s products; the impact of product liability lawsuits; the
influence of extensive and costly government regulation; and the
volatility of the trading price of the Company’s common stock.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221003005321/en/
Lisa M. Wilson In-Site Communications, Inc. 212-452-2793
lwilson@insitecony.com
TherapeuticsMD 561-961-1900 IR@TherapeuticsMD.com
Grafico Azioni TherapeuticsMD (NASDAQ:TXMD)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni TherapeuticsMD (NASDAQ:TXMD)
Storico
Da Set 2023 a Set 2024